Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
Researchers compared the efficacy and safety of cefiderocol vs high-dose, extended-infusion meropenem for adults with nosocomial pneumonia.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
Study authors described the prescribing patterns in children with community-acquired pneumonia, and assessed the relationship between narrow-spectrum antibiotics, broad-spectrum antibiotics, and macrolides with clinical outcomes.
The effect of appropriate antimicrobial therapy on 14-day mortality in patients severely ill with Acinetobacter baumannii bacteremic pneumonia was assessed, taking risk factors, patient demographics, and clinical characteristics into account.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Study authors assessed pneumococcal urinary antigen testing’s use in identifying patients for broad-spectrum antibiotic de-escalation, providing an opportunity for improved antimicrobial stewardship.
Researchers linked the use of 2 hypertension drug classes to lower mortality for those hospitalized with flu and pneumonia.
Pneumomediastinum, although a rare phenomenon, is more prevalent in patients with COVID-19 compared with historical patients with adult respiratory distress syndrome.
Patients with severe COVID-19 pneumonia had improved prognosis after receiving a short course of methyl-prednisolone pulses during the second week of disease.
Approximately 7% of pneumonia cases acquired in the intensive care unit can be classified as Staphylococcus aureus intensive care unit pneumonia.
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
Researchers compared HAdV-3 with HAdV-7 replication kinetics and host response in ex vivo human lung tissue cultures.
For patients with heart failure, influenza and pneumococcal vaccinations are associated with lower in-hospital mortality.
The aim of this study was to evaluate the invasive disease potential of non-PCV13 serotypes after implementation of this vaccine.
The ODYSSEY study is evaluating the efficacy and safety of tradipitant in adults with neurogenic inflammation of the lung secondary to COVID-19 infection.
The U.S. Centers for Disease Control and Prevention informed employees that office space it rents in the Atlanta area would be closed after Legionella, the bacteria that causes legionnaires disease, was found in the buildings.
ICD-9 organism-specific administrative codes for pneumonia appear to underestimate the prevalence of specific disease-associated pathogens in hospitalized patients.
Researchers found limited clinical variability between PIV serotypes and substantial overlap in presenting signs and symptoms for PIV and other etiologies.
Research results underscore the importance of understanding the characteristics of Legionnaires’ disease and the need for early diagnosis.